Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Which Stock Should You Track
- August 6, 2026
- Posted by: Ankit Jaiswal
- Category: News
Sun Pharma MCap Rs 4,70,270 Cr, PE 38.81x, ROE 13.74%. Dr Reddy’s MCap Rs 96,877 Cr, PE 30.43x, ROE 11.07%.
Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories is a comparison large pharma investors look up when evaluating India’s two largest pharmaceutical companies. Sun Pharma is India’s largest pharma company by market cap, known for its branded Indian formulations, US generics and growing specialty pharma portfolio including Ilumya (psoriasis) and Cequa (dry eye). Dr Reddy’s Laboratories is Hyderabad-based with strong US generics, API manufacturing and biosimilar aspirations.
This Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories article covers reach and market position, key products, latest declared results and stock valuation. The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.
Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Reach and Market Position
On the Sun Pharmaceutical Industries side of the Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison, Sun Pharma sells in over 100 countries with a large branded prescriptions business in India, a growing US specialty portfolio and generics across North America and Europe. Market capitalisation is Rs 4,70,270 Cr.
Click Here – Get Free Investment Predictions
On the Dr Reddy’s Laboratories side of the Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison, Dr Reddy’s Laboratories sells generics in the USA, Europe, Russia and India with a strong API business and emerging biosimilars programme. Market capitalisation is Rs 96,877 Cr.
Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Key Products and Business Mix
In the Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories product comparison, Sun Pharmaceutical Industries offers: Sun Pharma sells Ranbaxy heritage brands, Sun Pharma India brands, US specialty products and global generics. P/E is 38.81x, ROE 13.74 percent, debt to equity 0.06.
For Dr Reddy’s Laboratories in this Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories breakdown: Dr Reddy’s sells US generics, branded Indian formulations, APIs and biosimilars. P/E is 30.43x, ROE 11.07 percent, debt to equity 0.20.
Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Latest Results
The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories results for Sun Pharmaceutical Industries: Sun Pharma has a market cap of Rs 4,70,270 Cr and P/E of 38.81x. ROE is 13.74 percent. Sun Pharma is nearly 5 times larger than Dr Reddy’s by market cap.
The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories results for Dr Reddy’s Laboratories: Dr Reddy’s has a market cap of Rs 96,877 Cr and P/E of 30.43x, cheaper than Sun Pharma. ROE is 11.07 percent. Dividend yield is 0.69 percent.
Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Stock and Valuation
The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories stock comparison uses the latest available market data from Groww. Investors tracking Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories should verify current prices on NSE or BSE before trading.
Sun Pharma trades at a market cap of Rs 4,70,270 Cr and P/E of 38.81x with ROE of 13.74 percent. Dr Reddy’s trades at Rs 96,877 Cr market cap and P/E of 30.43x, significantly cheaper, with an ROE of 11.07 percent. Sun Pharma commands a premium for its specialty pharma pipeline and larger scale.
Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Quick Comparison Table
The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison table below summarises the key metrics covered in this article side by side.
| Parameter | Sun Pharmaceutical Industries | Dr Reddy’s Laboratories |
|---|---|---|
| Sector | Large-cap pharma: specialty, branded, generics | Large-cap pharma: US generics, API, biosimilars |
| Market Cap | Rs 4,70,270 Cr | Rs 96,877 Cr |
| P/E Ratio | 38.81x | 30.43x |
| ROE | 13.74% | 11.07% |
| Debt to Equity | 0.06 | 0.20 |
| Key products | US specialty (Ilumya, Cequa), India brands, generics | US generics, India branded, APIs, biosimilars |
| Headquarters | Mumbai | Hyderabad |
Conclusion
The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison above covers the key data points on reach, products, results and valuation. Sun Pharma vs Dr Reddy’s Laboratories are India’s two largest pharma companies. Sun Pharma is larger with a specialty pharma premium at a higher P/E. Dr Reddy’s is cheaper with strong US generic and API capabilities. Investors should review USFDA compliance, drug approvals and specialty pipeline and consult a SEBI-registered advisor before investing.
Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries and Dr Reddy’s Laboratories live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the main difference between Sun Pharma and Dr Reddy’s?
Ans. Sun Pharma is India’s largest pharma company with branded India prescriptions, US specialty pharma (Ilumya, Cequa) and global generics. Dr Reddy’s has strong US generic filings, an API business and emerging biosimilars.
Which stock trades at a lower P/E?
Ans. Dr Reddy’s trades at 30.43x trailing earnings, cheaper than Sun Pharma at 38.81x.
Which company has the higher ROE?
Ans. Sun Pharma has an ROE of 13.74 percent, higher than Dr Reddy’s at 11.07 percent.
What specialty products does Sun Pharma sell?
Ans. Sun Pharma sells Ilumya (ixekizumab for psoriasis) and Cequa (cyclosporine for dry eye disease) in the US through its specialty pharma division.
What are biosimilars at Dr Reddy’s?
Ans. Dr Reddy’s is developing biosimilar versions of biologic drugs for the US and global markets, which are complex biological medicines whose patents are expiring.
What risks apply to large pharma companies?
Ans. Both face risk from USFDA inspection observations at manufacturing plants, generic pricing erosion in the US, and new drug approval timelines.
Should I invest in Sun Pharma or Dr Reddy’s?
Ans. Sun Pharma is larger with specialty drug premium. Dr Reddy’s is cheaper with strong generics. Consult a SEBI-registered advisor before investing.
